BSE filing, NSE: EMMESSA. Summary written from the filing by ALFA Finder's alert engine.
Emmessar Biotech & Nutrition Ltd: key numbers
- Share price
- ₹22.74
- Market cap
- ₹11.36 Cr
- Revenue (annual)
- ₹0.37 Cr
- Net profit (annual)
- ₹0.44 Cr
- P/E (TTM)
- 28.7×Sector 52.0×
- Promoter holding
- 59.53%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emmessar Biotech & Nutrition Ltd
All →Emmessar Biotech & Nutrition Board Meeting Date
Emmessar Biotech & Nutrition scheduled a board meeting for 31 October 2026 to consider unaudited quarterly results ended 30 September 2026. The trading window stays closed until 02 November 2026.
Emmessar Biotech & Nutrition Other Announcement
Emmessar Biotech & Nutrition Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with regulatory reporting standards.
Emmessar Biotech & Nutrition Annual General Meeting
Emmessar Biotech & Nutrition Ltd conducted its 34th Annual General Meeting on September 29, 2026. Key business included adopting financial statements and re-appointing directors.
Emmessar Biotech & Nutrition Other Announcement
Emmessar Biotech & Nutrition informed shareholders without registered email addresses about accessing the Annual Report and 34th AGM Notice via the company's website.
Emmessar Biotech & Nutrition Annual General Meeting
Emmessar Biotech & Nutrition Limited has issued a notice for its 34th Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.
Emmessar Biotech & Nutrition Q1 FY27 Results: Net Profit ₹0.1 Cr, Down 50.0% YoY
Emmessar Biotech & Nutrition Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0.1 Cr (-50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.1 Cr · -50.0% YoY
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.